Colorado enrolls first patient in clinical trial of HDAC inhibitor, OKI-179

IMAGE: This is Jennifer Diamond, MD, primary investigator of OKI-179 clinical trial. view more  Credit: University of Colorado Cancer Center OnKure, Inc. and the University of Colorado Cancer Center today announced enrollment of the first patient in a first-in-human phase 1 clinical trial testing investigational anti-cancer agent OKI-179, a novel and Class-selective HDAC inhibitor, in patients…

Details